Issues in emerging health technologies
-
Issues Emerg Health Technol · Dec 2004
Randomized Controlled Trial Clinical TrialBevacizumab for advanced colorectal cancer.
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is thought that bevacizumab inhibits the formation of new blood vessels. ⋯ More studies are needed to compare the combination of bevacizumab plus IFL to other chemotherapy regimens used in the treatment of ACC. The addition of bevacizumab to 5-fluorouracil-based chemotherapy regimens will significantly increase the costs of palliation for ACC.